{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Liposomal+Amphotericin+B",
    "query": {
      "intervention": "Liposomal Amphotericin B"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Liposomal+Amphotericin+B&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T09:12:01.833Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00161356",
      "title": "Ambisome in Liver Transplant Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Liver Transplantation"
      ],
      "interventions": [
        {
          "name": "Ambisome",
          "type": "DRUG"
        },
        {
          "name": "Liver Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2005-09",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2008-06-23",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00161356"
    },
    {
      "nct_id": "NCT00106288",
      "title": "Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Candidiasis"
      ],
      "interventions": [
        {
          "name": "Micafungin",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Amphotericin B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 637,
      "start_date": "2003-01",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2014-09-18",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Orange, California • Denver, Colorado + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00106288"
    },
    {
      "nct_id": "NCT00885703",
      "title": "High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cryptococcal Meningitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Fluconazole",
          "type": "DRUG"
        },
        {
          "name": "Amphotericin B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2010-04-16",
      "completion_date": "2017-01-12",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00885703"
    },
    {
      "nct_id": "NCT00491426",
      "title": "Antimicrobial PK in Infants With Suspected or Confirmed Infection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Infection"
      ],
      "interventions": [
        {
          "name": "Ampicillin",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin/Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Acyclovir",
          "type": "DRUG"
        },
        {
          "name": "Amphotericin B",
          "type": "DRUG"
        },
        {
          "name": "Ambisome",
          "type": "DRUG"
        },
        {
          "name": "Anidulafungin",
          "type": "DRUG"
        },
        {
          "name": "Caspofungin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Days",
        "sex": "ALL",
        "summary": "Up to 120 Days"
      },
      "enrollment_count": 450,
      "start_date": "2006-01",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2012-11-19",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00491426"
    },
    {
      "nct_id": "NCT00002019",
      "title": "Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Meningitis, Cryptococcal",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Amphotericin B, Lipid-based",
          "type": "DRUG"
        },
        {
          "name": "Amphotericin B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Liposome",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 19,
      "location_summary": "Torrance, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002019"
    },
    {
      "nct_id": "NCT03327727",
      "title": "VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Aspergillosis",
        "Invasive Pulmonary Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Investigational Agent: VL-2397",
          "type": "DRUG"
        },
        {
          "name": "Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-02-20",
      "completion_date": "2019-01-14",
      "has_results": false,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03327727"
    },
    {
      "nct_id": "NCT00047827",
      "title": "Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Micafungin",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Amphotericin B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2,
      "start_date": "2002-12",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2014-08-20",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Ann Arbor, Michigan + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047827"
    },
    {
      "nct_id": "NCT00418951",
      "title": "Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Voriconazole",
          "type": "DRUG"
        },
        {
          "name": "Liposomal amphotericin B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2006-11",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2012-08-07",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00418951"
    },
    {
      "nct_id": "NCT06525389",
      "title": "Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Talaromycosis"
      ],
      "interventions": [
        {
          "name": "Liposomal Amphotericin B (LAmB)",
          "type": "DRUG"
        },
        {
          "name": "Flucytosine (5FC)",
          "type": "DRUG"
        },
        {
          "name": "Flucytosine (5FC) placebo pill",
          "type": "DRUG"
        },
        {
          "name": "Deoxycholate Amphotericin B (DAmB)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 428,
      "start_date": "2026-09-01",
      "completion_date": "2031-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06525389"
    },
    {
      "nct_id": "NCT05101187",
      "title": "Olorofim Aspergillus Infection Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Invasive Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Olorofim",
          "type": "DRUG"
        },
        {
          "name": "AmBisome®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "F2G Biotech GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2022-03-31",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-09-15T09:12:01.833Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Duarte, California • Sacramento, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05101187"
    }
  ]
}